Say Hello to Omnipod® 5

The Omnipod 5 Automated Insulin Delivery System (AID)

Omnipod 5 is the first and only tubeless, automated insulin delivery system integrated with the Dexcom G6 and G7 Sensors in Canada.

Omnipod 5 Features

  • SmartAdjust™ technology adjusts basal insulin automatically to help correct highs while proactively helping to protect from lows1,2
  • Integrated with Dexcom G6 and G7 Sensors
  • The first AID system with a SmartBolus calculator, informed with sensor values and trends
  • Activity Feature available in Automated Mode
  • Customized settings to personalize your insulin delivery by selecting basal profiles, target glucose levels, and bolus settings
  • Discreet, modern, intuitive touchscreen display

The Power of the Pod

  • Tubeless
    No need to make clothing choices to accommodate pumps, and no need to worry about tubes getting tangled or pulled
  • Wearable
    You can wear it almost anywhere an insulin injection can be given. Placement is easy, and the Pod Site Tracker feature promotes site rotation and skin integrity
  • Waterproof*
    No need to disconnect for swimming or bathing for up to 3 days (72 hours) of continuous insulin delivery
  • Auto-Cannula Insertion Hands free insertion (no need to see the insertion needle or cannula). The small, flexible cannula inserts with the push of a button
  • Flexible & Personalized
    Intuitively simple technology with precise insulin delivery based on rates programmed by the users or automated insulin delivery, depending on the pump
  • Proactive
    Communicates with the sensor every 5 minutes to predict where glucose will be 60 minutes into the future, and increases, decreases, or pauses basal insulin based on the user's customized Target Glucose settings†
  • Bluetooth® Enabled
    Communicates with the Controller via Bluetooth wireless technology

*The Pod has an IP28 rating for up to 7.6 metres (25 feet) for up to 60 minutes. The Omnipod 5 Controller is not waterproof. Please consult sensor manufacturer user guide for sensor waterproof rating.

†Compatible with the Dexcom G6 and Decom G7 Sensors. Sensor is required for Automated Mode. Boluses for meals and corrections are still necessary. Sensors are sold separately and require a separate prescription. The Dexcom Sensors must be used with the Dexcom mobile app. The Dexcom receiver is not compatible. Devices compatible with Dexcom apps can be found at https://dexcom.com/compatibility.

References:

1. Brown SA, et al. Diabetes Care. 2021;44(7):1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6-70 yrs [adults/adolescents (n=128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time (>10 mmol/L or >180 mg/dL) in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, p<0.0001, respectively. Mean time (<3.9 mmol/L or <70 mg/dL) in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.9% vs. 1.3%, p<0.0001; 2.2% vs. 1.8%, p=0.8153, respectively. Results measured by CGM. Study funded by Insulet.

2. Sherr JL, et al. Diabetes Care. 2022;45(8):1907-1910. Prospective trial in 80 participants with T1D aged 2-5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time (>10 mmol/L or >180 mg/dL) in very young children (2-5.9 yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, p<0.0001. Mean time (<3.9 mmol/L or <70 mg/dL) in very young children (2-5.9 yrs) as measured by CGM: ST = 3.43%, 3-mo Omnipod 5 = 2.46%, p=0.0204. Results measured by CGM. Study funded by Insulet.

3. Renard E, et al. Diabetes Care. 2024. doi:10.2337/dc24-1550. A 13-week randomised controlled trial conducted among 194 adults (age 18-70 years) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 Automated Insulin Delivery (AID) System versus conventional non-AID pump therapy and CGM (control). Mean Hypoglycemia Confidence Scale (HCS) total score at 13-weeks: Control = 3.14, Omnipod 5 = 3.40, Mean adjusted difference in change in HCS score, Omnipod 5-Control = 0.20, p=0.0048. Mean proportion of participants with clinically meaningful result ≥3 (%) at 13-weeks: Control = 61.7%, Omnipod 5 = 81.7%. Mean adjusted difference, Omnipod 5—Control = 18.9%, p=0.0076.